Rating Change
Guggenheim analysts initiated coverage on Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) with a rating of Buy on October 06, 2026.
new coverageNASDAQ:RAPP
Guggenheim Initiates Coverage on Rapport Therapeutics, Inc. Common Stock (RAPP) with Buy
Guggenheim analysts initiated coverage on Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) with a rating of Buy on October 06, 2026.
At publication ·
What changed
Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) · new coverage
- Firm
- Guggenheim
- Rating
- Buy
- Price at event
- $31.15
- Market capitalization
- $1.1B
At a glance
Key takeaways
- Guggenheim initiated Buy coverage on Rapport Therapeutics (RAPP) on October 6, 2026, with the stock trading at $31.15 and a market capitalization of $1.1 billion.
Market Context
Rapport Therapeutics, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $31.15 with a market capitalization of $1.1B.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Rapport Therapeutics, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Rapport Therapeutics, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 06, 2026 | Guggenheim | Buy | N/A |
| Sep 16, 2026 | BTIG | Buy | N/A |
| Aug 19, 2026 | BTIG | Buy | N/A |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 05, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View RAPP Stock Page
Frequently Asked Questions
What does the Buy rating mean for RAPP?
A rating of Buy from Guggenheim reflects the analyst's outlook on Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RAPP forecast page.